SCHEDULE: Blue Owl Capital Holdings LP Discloses Larimar Therapeutics Stake

Blue Owl Capital Holdings LP has filed a Schedule 13G, reporting beneficial ownership of 9.99% of Larimar Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Blue Owl Capital Holdings LP has filed a Schedule 13G, indicating it beneficially owns 10,739,492 shares of Larimar Therapeutics, Inc. common stock.
• This ownership stake represents 9.99% of the class of securities.
• The reported shares include 7,120,007 shares of common stock, 975,700 shares issuable upon exercise of call options, and 2,643,785 shares issuable upon conversion of Series A convertible preferred stock.
• The filing is an amendment (Amendment No. 3) to a previous filing.
• The reporting person, Blue Owl Capital Holdings LP, is organized in Delaware.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports an ownership stake and does not contain operational or financial performance data for the company itself.

Positives

• Blue Owl Capital Holdings LP has a significant stake in Larimar Therapeutics, Inc., potentially indicating confidence in the company's future.
• The ownership is reported as being acquired and held in the ordinary course of business, suggesting a standard investment approach rather than a hostile takeover attempt.

Negatives

• The filing does not contain specific financial performance data for Larimar Therapeutics, Inc., making it difficult to assess the company's current health from this document alone.
• The conversion of Series A preferred stock is subject to a 'conversion blocker' that limits beneficial ownership to 9.99%, suggesting potential limitations on further investment or influence.

Risks

• The 'conversion blocker' on Series A preferred stock may limit the Reporting Person's ability to increase their stake beyond 9.99%, potentially impacting future strategic involvement.
• The filing does not detail specific risks associated with Larimar Therapeutics, Inc.'s business operations or market position.

Future Outlook

The filing does not contain forward-looking statements or guidance from Larimar Therapeutics, Inc. It solely reports the ownership stake of Blue Owl Capital Holdings LP.

Management Comments

• "The reported securities represent: (i) 7,120,007 shares of Common Stock; (ii) 975,700 shares of Common Stock issuable upon exercise of 9,757 call options; and (iii) 2,643,785 shares of Common Stock issuable upon conversion of Series A convertible preferred stock ('Series A Preferred Stock')."
• "The reported percentage is calculated based on 103,882,937 shares of Common Stock outstanding as of March 17, 2026, as reported on the Issuer's 10-K filed with the Securities and Exchange Commission on March 19, 2026, as increased by (i) 975,700 shares of Common Stock issuable upon exercise of 9,757 call options and (ii) 2,643,785 shares of Common Stock issuable upon conversion of Series A Preferred Stock."
• "Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of the reported securities, for purposes of Section 13(d) and/or Section 13(g) or for any other purpose."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Blue Owl Capital Holdings LP's strategic interest in Larimar Therapeutics, Inc., a biotechnology company, which is a sector often subject to substantial institutional investment due to growth potential and M&A activity.

Stakeholder Impact

• Shareholders: The increased institutional ownership by Blue Owl Capital Holdings LP may be viewed positively by some shareholders, potentially indicating confidence in the company's prospects. However, the 9.99% ownership cap due to conversion blockers might limit the extent of this influence.
• Management: The filing does not directly impact management's day-to-day operations but signifies a significant shareholder whose actions or potential future involvement could influence strategic decisions.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Blue Owl Capital Holdings LP will continue to hold its shares in Larimar Therapeutics, Inc., subject to the terms of the Series A convertible preferred stock and any applicable regulations.
• Larimar Therapeutics, Inc. will continue its business operations, with the ownership structure now updated to reflect Blue Owl Capital Holdings LP's stake.

Key Dates

Keywords

Schedule 13G, Larimar Therapeutics, Blue Owl Capital Holdings LP, Beneficial Ownership, Common Stock, Series A Convertible Preferred Stock, Call Options, SEC Filing, Investment